{"version":"1.0","type":"link","title":"Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.","author_name":"Gao Z 외","author_url":"https://prs-insight.online/author/Gao%20Z","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/95389","thumbnail_width":1200,"thumbnail_height":630}